New pill could ease psoriatic arthritis pain in 12 weeks
NCT ID NCT07315061
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests an experimental oral drug called D-2570 in 222 adults with active psoriatic arthritis. Participants take the drug or a placebo daily for 12 weeks. The main goal is to see if D-2570 reduces joint tenderness and swelling by at least 20% compared to placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- D-2570
- What this could lead to
- If successful, D-2570 could offer a new oral treatment option to reduce joint pain and swelling in people with active psoriatic arthritis.
- What could go wrong
- This is an early Phase 2 trial with a small number of participants. The drug may not work better than placebo, and side effects are still being studied.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSA (PSORIATIC ARTHRITIS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
West China School of Medicine
RECRUITINGChengdu, Sichuan, 610041, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.